2 Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a

- 3 gimbal mounted linac
- 4

```
5 Authors:
```

- 6 Yukinori Matsuo, MD, PhD¹; Nami Ueki, MD, PhD¹; Kenji Takayama, MD²; Mitsuhiro Nakamura,
- 7 PhD¹; Yuki Miyabe, MS¹; Yoshitomo Ishihara, MS¹; Nobutaka Mukumoto, PhD¹; Shinsuke Yano, RTT³;
- 8 Hiroaki Tanabe, MS²; Shuji Kaneko, BS^{1, 4}; Takashi Mizowaki, MD, PhD¹; Hajime Monzen, PhD¹;
- 9 Akira Sawada, PhD^5 ; Masaki Kokubo, MD, PhD^6 ; and Masahiro Hiraoka, MD, PhD^1 .
- 10

11 Affiliations:

- 12 1. Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School
- 13 of Medicine, Kyoto, Japan
- 14 2. Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan
- 15 3. Clinical Radiology Service Division, Kyoto University Hospital, Kyoto, Japan
- 16 4. Mitsubishi Heavy Industries, Ltd., Tokyo, Japan
- 17 5. Faculty of Medical Science, Kyoto College of Medical Science, Nantan, Japan

18	6.	Department of Rad	iation Oncology,	Kobe City	Medical Center	General Hospita	l, Kobe, Jar	oan

20 **Corresponding author:**

- 21 Yukinori Matsuo, MD, PhD.
- 22 Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto
- 23 University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
- 24 Phone: +81-75-751-3762, fax: +81-75-771-9749
- 25 E-mail: ymatsuo@kuhp.kyoto-u.ac.jp
- 26
- 27 This paper consists of 21 pages and 2 tables. There are 2 supplementary figures.
- 28
- 29 **Running head**:
- 30 Dynamic tracking with real-time monitoring
- 31
- 32 **Keywords:** stereotactic body radiotherapy; lung cancer; dynamic tumour tracking; real-time monitoring;
- 33 feasibility study
- 34

35 Abstract:

36 **Purpose:** To evaluate feasibility and acute toxicities after dynamic tumour tracking (DTT) irradiation

- 37 with real-time monitoring for lung tumours using a gimbal mounted linac.
- 38Materials and Methods: Spherical gold markers were placed around the tumour using a bronchoscope 39 prior to treatment planning. Prescription dose at the isocentre was 56 Gy in 4 fractions for T2a lung cancer and metastatic tumour, and 48 Gy in 4 fractions for the others. Dose-volume metrics were 4041compared between DTT and conventional static irradiation using in-house developed software. 42**Results:** Of twenty patients enrolled, DTT radiotherapy was successfully performed for 16 patients, 43except 4 patients who coughed out the gold markers, one who showed spontaneous tumour regression, 44and one where the abdominal wall motion did not correlate with the tumour motion. Dose 45covering 95% volume of GTV was not different between the two techniques, while normal lung volume 46receiving 20 Gy or more was reduced by 20%. A mean treatment time per fraction was 36 minutes using 47DTT. With a median follow-up period of 13.2 months, no severe toxicity grade 3 or worse was observed. 48**Conclusions:** DTT radiotherapy using a gimbal mounted linac was clinically feasible for lung treatment 49without any severe acute toxicity. 50

51

52 Introduction

68

53Lung cancer is the leading cause of cancer-related deaths in most countries, including the US[1] and 54Japan^[2]. There have been two trends in lung cancer in recent years. The first is the shift in the patient 55population to older ages[1,2], and the second is the gradual increase in the ratio of early stage lung 56cancer[3,4]. Thus, development of a new treatment modality that is appropriate for elderly patients with 57early stage lung cancer is desirable. 58Stereotactic body radiotherapy (SBRT) was developed as a new treatment modality for early stage lung 59cancer in the late 1990s. Many retrospective studies and several multi-institutional prospective trials 60 have demonstrated that excellent local control is obtained by SBRT, with acceptable toxicity[5–7]. Thus, 61SBRT is now an important treatment option for patients with early stage non-small-cell lung cancer who 62 are medically inoperable and those who are elderly and relatively unfit for surgery. 63 The next innovation expected for lung SBRT is four-dimensional (4D) radiotherapy, which can cope 64 with tumour movement. The lung expands periodically according to respiration and a lung tumour 65 moves mainly in the craniocaudal direction. The amplitude of craniocaudal tumour motion is around 1 66 cm in mean, but can be 3-4 cm in some patients[8]. When the whole trajectory of a moving tumour is 67 included in the irradiation field, larger volumes of healthy tissues are irradiated. The latter leads to a risk

of toxicity[9–11], and accordingly, that might limit the indication of SBRT to smaller tumours. A new 4D

71 indications of SBRT.

69

70

72The Vero4DRT (formerly called the MHI-TM2000; Mitsubishi Heavy Industries Ltd., Tokyo, Japan, and 73BrainLab AG, Feldkirchen, Germany)[12] has two special features that allow dynamic tumour tracking 74(DTT) with real-time monitoring. One is two sets of kilovoltage (kV) x-ray imagers, that can monitor the 75three-dimensional position of the tumour in real-time via implanted fiducial markers, and the other is a 76gimbal mounted linac, enabling DTT. Extensive evaluation of the characteristics of this DTT system 77demonstrated high accuracies in treatment delivery to a moving target [13–17]. Previous experimental 78validation offered the required confidence for clinical implementation of DTT treatment of lung tumours. 79The purpose of this study was to evaluate feasibility and acute toxicities after DTT radiotherapy with 80 real-time monitoring in SBRT for lung cancers using the Vero4DRT system.

81

82 Materials and Methods

83 Patients

Eligibility criteria were as follows: (1) a single lung tumour with a diameter of 50 mm or less, (2) no
nodal or distant metastasis, (3) respiratory tumour movement of 5 mm or more, (4) age of 20 years or

86	above, (5) performance status of 0-2, (6) arms could be held over the head for 30 min or more, (7) doses
87	to adjacent organs not exceeding the pre-determined constraints, which were the same as in the Japan
88	Clinical Oncology Group protocol 0403[18], and (8) written informed consent. This study was approved
89	by the institutional review board. It was registered with the UMIN Clinical Trials Registry in Japan
90	(UMIN000005324).
91	
92	Pre-planning procedures
93	Prior to treatment planning, spherical gold markers with a diameter of 1.5 mm (FMR-201CR; Olympus

94 Medical Systems, Tokyo, Japan) were placed around the tumour under bronchoscopic guidance as an

95 internal surrogate for the tumour position. Treatment planning was carried out 1 week after insertion of

96 the gold markers. At least 3 markers were required for the DTT irradiation to be performed.

97 On the simulation day, the patient was fixed in a supine position with both arms raised using an

- 98 individualized vacuum pillow (BodyFIX; Elekta AB, Stockholm, Sweden, or ESFORM; Engineering
- 99 System, Matsumoto, Japan). Ten respiratory phases of 4D CT were acquired in axial cine mode using a

100 16-slice CT scanner (LightSpeed RT16 or BrightSpeed Elite; GE Healthcare, Little Chalfont, UK) and a

- 101 real-time positioning management system (Varian Medical Systems, Palo Alto, US). Immediately after
- 102 the 4D CT scan, a breath-hold CT scan was also acquired at the end of exhalation. The breath-hold CT

103	was sent to iPlan RT image (ver. 4.1; BrainLab AG) as a reference image. The coordinate for each phase
104	image from the 4D CT was modified so that its centroid of the fiducial markers was matched with that in
105	the breath-hold CT. Then, the 10 phase images were fused onto the breath-hold CT. After the CT scan,
106	the patient was moved to the Vero4DRT to perform a 4D modelling[14], which correlates the external
107	abdominal motion and the internal fiducial motion. The purpose of the modelling was to estimate the 4D
108	modelling error and the peak-to-peak amplitude of tumour motion.
109	
110	Treatment planning
111	Gross tumour volumes (GTVs) were delineated on the breath-hold CT and 10 phase images. An internal
112	target volume for tracking (ITV) was defined as a composite of the eleven GTVs from the breath-hold
113	CT and the 10 phase images (Supplementary Fig. 1). Because the phase images were registered based on
114	the marker centroid, the ITV was supposed to compensate for tumour deformation and uncertainty in the
115	positional relationship between the tumour and fiducial makers during respiration[19]. Planning target
116	volume (PTV) for tracking was defined as the ITV plus setup error and additional margins to
117	compensate the 4D modeling error, baseline drift of the abdominal position, and mechanical errors of the
118	system. The setup error was estimated to be 2.5 mm in each direction as an inter-fraction positional
119	variation between the fiducials and the tumour[19]. A margin for the 4D modelling error was defined as

a mean plus 2 times of standard deviation in the 4D model on the simulation day. A margin for the 121baseline drift was estimated as 10% of the tumour motion amplitude. The mechanical errors were 122defined as 0.5 mm[12]. The PTV margin was defined as a linear sum of these errors. At least 5 mm was 123required for the margin.

124Monitor units (MUs) for the treatment beams were calculated using the X-ray voxel Monte Carlo 125algorithm in iPlan RT dose (ver. 4.5.1; BrainLab AG) on the breath-hold exhale CT. The prescription 126dose was 48 Gy in four fractions for stage IA lung cancer, and 56 Gy in four fractions for stage IB lung 127cancer and metastatic lung tumour. This dose was prescribed at the isocentre. We typically arranged 128seven beams: four non-coplanar and three coplanar beams. 6-MV x-ray beams were collimated to the 129PTV plus 5-mm margin with a multi-leaf collimator. A static SBRT plan with non-tracking beams, based 130on the motion-encompassing method[8], was also prepared as a backup if DTT irradiation could not be 131achieved for some reason. Dose distributions were evaluated with an in-house developed software that 132allows 4D dose calculation considering with the gimbal mounted linac[20]. The calculated dose 133distributions for the 10 phase CT images were accumulated into the exhale breath-hold CT with 134deformable image registration using MIM Maestro (ver. 5.2; MIM Software Inc., Cleveland, OH). If the 135dose-volume metrics in the tracking plan were diagnosed to be superior to those in the static plan, the 136patient underwent DTT irradiation.

138 Irradiation of treatment beams

139First, the patient was laid on the pre-formed vacuum pillow. Set-up error was corrected for bony 140structures using the ExacTrac X-ray system. Second, a 4D model was built to correlate the infra-red 141markers on the abdomen with the internal fiducial markers. Then, irradiation could start in dynamic 142tracking mode with the beam following a location predicted by the 4D model based on the infra-red 143markers placed on the patient's abdominal wall. During irradiation, the tumour and the internal fiducials 144were monitored visually every second with EPID and the kV imagers. If the fiducial markers displaced 145from the predicted positions by 3 mm or more in 3 consecutive frames on the kV images, the irradiation 146was interrupted and rebuilding the 4D model was considered. 147

148 Follow-up after treatment

149 Follow-up visits were planned at 2, 4, 6, 9, and 12 months within the initial year after SBRT and every 3

- 150 months thereafter. A CT scan was performed at each visit. The follow-up period was defined as the
- 151 duration between the first day of treatment and the last follow-up visit or the date of death. Acute
- 152 toxicity was defined as any treatment-related toxicities during the initial 6 months after the treatment.
- 153 Toxicity grading was according to the Common Terminology Criteria for Adverse Events v.4.0.

155 Results

156Twenty-two patients were enrolled into this study between August 2011 and July 2013. No patients 157experienced toxicities related to the insertion of fiducial markers. Twenty-two of the 101 inserted 158markers were coughed out before the CT simulation. Consequently, the number of remaining makers in 1594 patients decreased to two, which is insufficient for DTT to be performed. The planning procedures for 160DTT could not be performed in another two patients. One patient showed thoracic breathing that 161 prevented the Vero system from tracking a tumour based on the abdominal motion (Supplementary Fig. 1622). In the other patient with histology-unproven primary lung cancer, the tumour spontaneously 163regressed during 10 days between the fiducial insertion and the simulation. For the remaining 16 patients, 164the CT simulation for DTT was successfully performed. Characteristics of the 16 patients are shown in 165Table 1. The mean PTV volume reduced from 56.2 cm³ to 39.6 cm³ for the static and tracking plans, respectively 166167(Table 2). GTV doses were not spoiled by the tracking method (dose covering 95% volume of GTV, 16893.4% vs. 93.7% of the prescription dose; p = 0.323 by paired *t*-test). Doses to the normal lung and liver

- 169 were reduced in the 16 patients. Lung V20, the relative volume receiving 20 Gy or more, was reduced by
- 170 19.5%, from 5.5% to 4.4%. The tracking plan showed a higher maximal dose to the spinal cord than the

171	static plan in 5 patients. However, the difference did not exceed 0.3 Gy and was considered to be
172	clinically acceptable.
173	The DTT irradiation was completed for all 64 fractions for the 16 patients. Mean and standard deviation
174	in treatment time per fraction were 36.2 and 8.8 minutes (range, 19-70 minutes), respectively. The
175	treatment time exceeded 50 minutes in 5 fractions because of communication failures between the
176	tracking system and the gimbal system requiring a restart of the tracking procedure. The gold markers
177	were well recognized with kV x-ray imagers throughout all treatment fractions. The 4D modelling was
178	performed a mean of 1.9 times per fraction (range, 1 to 4).
179	With a median follow-up period of 13.2 months (range, 3.4–26.5 months), one patient experienced grade
180	2 radiation pneumonitis. No severe toxicity grade 3 or worse has been observed in any of the patients.
181	Two patients died of cancer, and one died of infectious pneumonia. Local tumour control was achieved
182	except one patient who developed local recurrence at 12.0 months.
183	
184	Discussion
185	The Vero4DRT system has two major advantages. The first is that tumour position can be monitored in
186	real time using kV imagers and an EPID. The second is that no extra treatment time over static SBRT

187 and no special training for breath control are needed for the 4D treatment, which is clinically beneficial

189	Several uncertainties are associated with 4D irradiation, including tumour position prediction errors and
190	mechanical errors in beam delivery, which are problems to be overcome. In the Vero4DRT, kV imagers
191	can ensure that the positions of the tumour and fiducial markers correspond to the predicted sites. EPID
192	can be used to verify the tumour position in complement to the kV imagers[21]. Furthermore, log files
193	allow retrospective confirmation of the accuracy in the delivery of tumour tracking after treatment. Our
194	previous study, which evaluated the initial 10 patients from the present study cohort, confirmed high
195	accuracies in the tracking performance. The 95th percentiles of overall tracking errors were 1.3 mm, 2.4
196	mm and 1.4 mm in left-right, cranio-caudal and anterior-posterior directions, respectively[22].
197	The Task Group 76 of the American Association of Physicists in Medicine classified motion
197 198	The Task Group 76 of the American Association of Physicists in Medicine classified motion management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced
198	management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced
198 199	management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced shallow breathing with abdominal compression, and real-time tumour-tracking methods[8]. The
198 199 200	management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced shallow breathing with abdominal compression, and real-time tumour-tracking methods[8]. The motion-encompassing method is the most conventional and well-established. However, it uses the largest
198 199 200 201	management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced shallow breathing with abdominal compression, and real-time tumour-tracking methods[8]. The motion-encompassing method is the most conventional and well-established. However, it uses the largest field of the five methods, with a large PTV. The breath-hold technique and abdominal compression are

205	a shorter treatment time than the breath-hold methods or the gating methods, and a comparable treatment
206	time to the motion-encompassing methods. Dynamic tumour tracking is considered to be the favourable
207	method among the five motion management methods from the patient compliance and comfort points of
208	view. According to a Japanese survey of SBRT in 2009[23], the most frequent response regarding the
209	time needed for a single daily fraction was 30 min, followed by 40 min. Our result of 36.2 min for a
210	single fraction was thus comparable with standard times for SBRT in Japan. In addition to patient
211	comfort, a few studies have suggested that prolongation of the treatment time for a single fraction may
212	reduce its biological effectiveness[24,25]. Unfortunately, considerable prolongation of treatment time
213	over 50 minutes occurred in 5 fractions in the present study. The cause for the prolongation was
214	immaturity of the tracking system including software. To realize DTT irradiation, the tracking software
215	needed to communicate with other systems in real time and to command several operations including
216	control of the gimbal motion, process of signals from the infra-red camera and analysis of images from
217	the kV x-ray imagers. The tracking system had initial instability in the communication process where the
218	system could not simultaneously execute such different tasks. Some adaptations to the tracking system
219	have been introduced after the present study with the aim of improving stability. Volumetric modulated
220	arc therapy, which can reduce total MUs and consequently reduce treatment time, is being applied to
221	SBRT for the lung[26]. Arc irradiation application to DTT is needed for reduction of treatment time with

223conformal arc DTT irradiation as that with fixed-port DTT[27]. A treatment planning system capable of 224VMAT plan is under development for the Vero4DRT. 225The disadvantages of the current Vero4DRT system are its dependence on 4D modeling and fiducial 226marker insertion. If no appropriate 4D model is acquired, dynamic tracking cannot be performed, as 227occurred in one patient. One solution for this issue is to track a tumour based on real-time stereo 228fluoroscopy without any 4D model. However, this method introduces another problem of skin doses due 229to the continuous fluoroscopy during a treatment time. Another way to improve the 4D model is a 230training to encourage for patients to perform periodical abdominal breathing[28]. 231The Vero4DRT currently requires fiducial markers with x-ray fluoroscopy monitoring to detect the 232tumour position and create the 4D model. Two types of fiducials are applicable to the Vero4DRT: one is 233a spherical marker, and the other is a cylindrical marker. We used the spherical gold markers that were 234inserted into a peripheral bronchiole under bronchoscopy. This method was reported in more detail by 235Imura et al. from Hokkaido University[29]. All 57 patients in their report tolerated the marker 236implantation procedure and only one experienced pneumothorax, which resolved with bed rest. The 237toxicity rate was much lower than those of percutaneous insertion methods [30,31]. Trade-offs, however, 238for the reduced toxicity are marker dislocation between insertion and radiotherapy, and positional

the Vero4DRT. The Vero4DRT achieved the same level of geometric and dosimetric accuracy with

222

239	uncertainty between the tumour and makers. Imura et al. reported that 25% of the inserted markers could
240	not be detected throughout the treatment period. Indeed, 22% of the markers in this study were coughed
241	out before the CT simulation, and 4 of 22 (18%) patients could not undergo the DTT due to the marker
242	dislocation. The reason why the Vero4DRT system requires 3 markers or more in the use of spherical
243	markers is to detect the marker dislocation. Regarding the positional uncertainty between the tumour and
244	markers, Ueki et al. evaluated intra- and interfractional variations[19]. Root mean squares in the
245	intrafractional variations were 0.6 mm, 0.9 mm and 1.5 mm in the right-left, anteroposterior and
246	craniocaudal directions, respectively. Moderate correlations of the intrafractional variation with tumour
247	motion amplitude and tumour-marker distance were observed with correlation coefficients of 0.549-
248	0.780. However, the intrafractional error did not always distribute symmetrically around zero, but often
249	distributed in one side above or below zero. The direction and amplitude of the intrafractional variations
250	varied between patients. Base on the results, we judged that a uniform isotropic margin was inadequate
251	to cover the intrafractional variations, and that the fused CT approach as in the Method section was
252	suitable for DTT planning. The interfractional variation could be covered by a 2.5-mm margin.
253	In conclusion, DTT radiotherapy with real-time monitoring using a gimbal mounted linac was clinically
254	feasible for the lung without any severe acute toxicity.

256 **Conflict of interests:**

207 1.1.1., M.R. and M.H. have consultancy agreements with Mitsubish field y industries Edd., Japan	and M.H. have consultancy agreements with Mitsubishi Heavy Industries Ltd., Japan.	y agreements with Mitsubishi Heavy Industries Ltd., J	T.M., M.K. and M.H. have consultancy	257 T.I
---	--	---	--------------------------------------	---------

258 sponsored research program is provided by Mitsubishi Heavy Industries Ltd.

259

260 **Funding resources:**

- 261 This research was funded by the Japan Society for the Promotion of Science (JSPS) through the
- 262 "Funding Program for World-Leading Innovative R&D in Science and Technology (FIRST) Program,"
- 263 initiated by the Council for Science and Technology Policy (CSTP).
- 264 The funding program had no effect on the study design or the interpretation of data.

265

266

267 **References**

- 268 [1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
- 269 [2] Foundation for Promotion of Cancer Research. Cancer Statistics in Japan-2013 Available at:
- 270 http://ganjoho.jp/pro/statistics/en/backnumber/2013_en.html. Accessed January 10, 2014.
- [3] Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer
 registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J
 Thorac Oncol 2011;6:1229–35.

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5:29–33.

276 [5] Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body
277 radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070–6.

274

275

[4]

- [6] Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Stereotactic Body
 Radiation Therapy For T1N0M0 Non-small Cell Lung Cancer: First Report for Inoperable Population
 of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys
 281 2012;84:S46.
- [7] Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. A Phase II Trial of
 Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-small Cell Lung Cancer: Japan
 Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys 2010;78:S27–8.
- [8] Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, et al. The management of
 respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys 2006;33:3874–
 900.
- Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al. Dose-volume
 metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
 Int J Radiat Oncol Biol Phys 2012;83:e545–9.
- [10] Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, et al. Dose-response relationship
 for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol
 2010;97:65–70.
- [11] Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Bengua G, et al. Radiation pneumonitis
 after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. Int
 J Radiat Oncol Biol Phys 2010;77:1596–603.
- [12] Kamino Y, Takayama K, Kokubo M, Narita Y, Hirai E, Kawawda N, et al. Development of a
 four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol
 Biol Phys 2006;66:271–8.

300	[13]	Mukumoto N, Nakamura M, Sawada A, Takahashi K, Miyabe Y, Takayama K, et al. Positional
301		accuracy of novel x-ray-image-based dynamic tumor-tracking irradiation using a gimbaled MV x-ray
302		head of a Vero4DRT (MHI-TM2000). Med Phys 2012;39:6287–96.
303	[14]	Mukumoto N, Nakamura M, Sawada A, Suzuki Y, Takahashi K, Miyabe Y, et al. Accuracy
304		verification of infrared marker-based dynamic tumor-tracking irradiation using the gimbaled x-ray
305		head of the Vero4DRT (MHI-TM2000). Med Phys 2013;40:041706.
306	[15]	Depuydt T, Verellen D, Haas O, Gevaert T, Linthout N, Duchateau M, et al. Geometric accuracy of a
307		novel gimbals based radiation therapy tumor tracking system. Radiother Oncol 2011;98:365–72.
308	[16]	Nakamura M, Sawada A, Ishihara Y, Takayama K, Mizowaki T, Kaneko S, et al. Dosimetric
309		characterization of a multileaf collimator for a new four-dimensional image-guided radiotherapy
310		system with a gimbaled x-ray head, MHI-TM2000. Med Phys 2010;37:4684–91.
311	[17]	Takayama K, Mizowaki T, Kokubo M, Kawada N, Nakayama H, Narita Y, et al. Initial validations
312		for pursuing irradiation using a gimbals tracking system. Radiother Oncol 2009;93:45–9.
313	[18]	Matsuo Y, Takayama K, Nagata Y, Kunieda E, Tateoka K, Ishizuka N, et al. Interinstitutional
314		variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol
315		Phys 2007;68:416–25.
316	[19]	Ueki N, Matsuo Y, Nakamura M, Mukumoto N, Iizuka Y, Miyabe Y, et al. Intra- and interfractional
317		variations in geometric arrangement between lung tumours and implanted markers. Radiother Oncol
318		2014;110:523–8.
319	[20]	Ishihara Y, Sawada A, Nakamura M, Mukumoto N, Kaneko S, Takayama K, et al. Development of
320		Monte Carlo Dose Calculation System for Tumor-Tracking Irradiation with a Gimbaled X-Ray Head.
321		Med Phys 2011;38:3644.
322	[21]	Poels K, Depuydt T, Verellen D, Engels B, Collen C, Heinrich S, et al. A complementary
323		dual-modality verification for tumor tracking on a gimbaled linac system. Radiother Oncol
324		2013;109:469–74.

325	[22]	Mukumoto N, Nakamura M, Yamada M, Takahashi K, Tanabe H, Yano S, et al. Intrafractional
326		tracking accuracy in infrared marker-based hybrid dynamic tumour-tracking irradiation with a
327		gimballed linac. Radiother Oncol 2014;111:301–5.
328	[23]	Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic
329		body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int
330		J Radiat Oncol Biol Phys 2009;75:343–7.
331	[24]	Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat
332		Oncol Biol Phys 2004;59:242–9.
333	[25]	Shibamoto Y, Otsuka S, Iwata H, Sugie C, Ogino H, Tomita N. Radiobiological evaluation of the
334		radiation dose as used in high-precision radiotherapy: effect of prolonged delivery time and
335		applicability of the linear-quadratic model. J Radiat Res 2012;53:1–9.
336	[26]	Verbakel WF a R, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ. Rapid delivery of stereotactic
337		radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol
338		2009;93:122–4.
339	[27]	Ono T, Miyabe Y, Yamada M, Shiinoki T, Sawada A, Kaneko S, et al. Geometric and dosimetric
340		accuracy of dynamic tumor-tracking conformal arc irradiation with a gimbaled x-ray head. Med Phys
341		2014;41:031705.
342	[28]	Nakamura M, Sawada A, Mukumoto N, Takahashi K, Mizowaki T, Kokubo M, et al. Effect of audio
343		instruction on tracking errors using a four-dimensional image-guided radiotherapy system. J Appl
344		Clin Med Phys 2013;14:255–64.
345	[29]	Imura M, Yamazaki K, Shirato H, Onimaru R, Fujino M, Shimizu S, et al. Insertion and fixation of
346		fiducial markers for setup and tracking of lung tumors in radiotherapy. Int J Radiat Oncol Biol Phys
347		2005;63:1442–7.
348	[30]	Kothary N, Heit JJ, Louie JD, Kuo WT, Loo BW, Koong A, et al. Safety and efficacy of percutaneous
349		fiducial marker implantation for image-guided radiation therapy. J Vasc Interv Radiol 2009;20:235-9.

350	[31]	Hong JC, Yu Y, Rao AK, Dieterich S, Maxim PG, Le Q-T, et al. High retention and safety of
351		percutaneously implanted endovascular embolization coils as fiducial markers for image-guided
352		stereotactic ablative radiotherapy of pulmonary tumors. Int J Radiat Oncol Biol Phys 2011;81:85–90.

354	Figure	legend
-----	--------	--------

355 Supplementary figure 1. A schema for definition of an internal target volume (ITV) for

356 tracking

357 a) An example of intrafractional change in alignment of gross tumour volume (GTV) and


- 358 fiducial markers, and intrafractional tumour deformation.
- b) Definition of ITV for tracking. The GTVs are fused based on the marker centroids. Then,
- 360 an ITV for tracking (the thick red line) is defined as a composite of the fused GTVs.
- 361 c) A screenshot from a case. Several lines with various colours are shown around the
- 362 tumour, which indicate GTVs from phase images of 4D CT. An ITV (not shown) is defined as
- 363 a volume including all the GTVs. The outermost pink line indicates a planning target


364 volume for the ITV.


365

366 Supplementary figure 2. A patient who showed thoracic breathing


367	The tumour position in the superior-inferior (SI) direction and the abdominal wall position
368	in the anterior-posterior (AP) direction are shown in blue and red lines, respectively. Note
369	that the patient showed thoracic breathing where the tumour moved without any
370	abdominal motion during the initial 10 seconds. Thoracic breathing was the dominant
371	respiratory pattern in the patient so that the Vero system could not create an appropriate
372	4D model for the patient.














Time [sec]